HRP20041234B1 - Oblik pramipeksola za doziranje jednom dnevno - Google Patents

Oblik pramipeksola za doziranje jednom dnevno

Info

Publication number
HRP20041234B1
HRP20041234B1 HRP20041234AA HRP20041234A HRP20041234B1 HR P20041234 B1 HRP20041234 B1 HR P20041234B1 HR P20041234A A HRP20041234A A HR P20041234AA HR P20041234 A HRP20041234 A HR P20041234A HR P20041234 B1 HRP20041234 B1 HR P20041234B1
Authority
HR
Croatia
Prior art keywords
pramipexole
hours
absorption
reach
approximately
Prior art date
Application number
HRP20041234AA
Other languages
English (en)
Inventor
Ernest J. Lee
Gerard M. Bredael
John R. Baldwin
Steven R. Cox
Mark J. Heintz
Original Assignee
Pharmacia Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31192088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20041234(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Corporation filed Critical Pharmacia Corporation
Publication of HRP20041234A2 publication Critical patent/HRP20041234A2/hr
Publication of HRP20041234B1 publication Critical patent/HRP20041234B1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Farmaceutska oralno primjenjiva smjesa obuhvaća terapijski učinkovitu količinu pramipeksola ili njegove farmaceutski prihvatljive soli i najmanje jedan farmaceutski prihvatljiv ekscipijent, spomenuta smjesa pokazuje najmanje jedno od (a) in vitro profil otpuštanja pri čemu se prosječno ne otapa više od oko 20% pramipeksola unutar 2 sata nakon stavljanja smjese u standardni test otapanja; i (b) in vivo apsorpcijski profil pramipeksola nakon jedne doze dane zdravoj odrasloj osobi pri čemu je vrijeme da bi se dosegla srednja vrijednost od 20% apsorpcije veće nego otprilike 2 sata i/ili je vrijeme da bi se dosegla srednja vrijednost od 40% apsorpcije veće od otprilike 4 sata. Smjesa je korisna za oralnu primjenu, ne više od jednom dnevno, subjektu koji ima stanje ili poremećaj za koji je indiciran agonist dopamin receptora.
HRP20041234AA 2002-07-25 2004-12-30 Oblik pramipeksola za doziranje jednom dnevno HRP20041234B1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39842702P 2002-07-25 2002-07-25
US39844702P 2002-07-25 2002-07-25
US47951403P 2003-06-18 2003-06-18
PCT/US2003/023522 WO2004010999A1 (en) 2002-07-25 2003-07-25 Pramipexole once-daily dosage form

Publications (2)

Publication Number Publication Date
HRP20041234A2 HRP20041234A2 (en) 2005-04-30
HRP20041234B1 true HRP20041234B1 (hr) 2013-07-31

Family

ID=31192088

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20041234AA HRP20041234B1 (hr) 2002-07-25 2004-12-30 Oblik pramipeksola za doziranje jednom dnevno

Country Status (40)

Country Link
US (2) US8679533B2 (hr)
EP (2) EP1536792B1 (hr)
JP (1) JP4607584B2 (hr)
KR (2) KR20050025654A (hr)
CN (1) CN1671381B (hr)
AP (1) AP2223A (hr)
AR (1) AR040682A1 (hr)
AU (1) AU2003256921B2 (hr)
BR (1) BR0312948A (hr)
CA (1) CA2493629C (hr)
CU (1) CU23468B7 (hr)
CY (2) CY1114263T1 (hr)
DE (1) DE20321906U1 (hr)
DK (2) DK1536792T3 (hr)
EA (1) EA017595B1 (hr)
EC (1) ECSP055569A (hr)
ES (2) ES2436745T3 (hr)
GE (1) GEP20074047B (hr)
HK (1) HK1078007A1 (hr)
HR (1) HRP20041234B1 (hr)
IL (1) IL166076A0 (hr)
IS (1) IS7613A (hr)
MA (1) MA27372A1 (hr)
ME (1) ME00347B (hr)
MX (1) MXPA05000980A (hr)
MY (1) MY142204A (hr)
NO (1) NO20050481L (hr)
NZ (1) NZ562681A (hr)
OA (1) OA12889A (hr)
PA (1) PA8578501A1 (hr)
PE (1) PE20040134A1 (hr)
PL (1) PL375444A1 (hr)
PT (2) PT1536792E (hr)
RS (1) RS52764B (hr)
SG (1) SG177011A1 (hr)
SI (2) SI2289514T1 (hr)
TW (1) TWI351955B (hr)
UY (1) UY27913A1 (hr)
WO (1) WO2004010999A1 (hr)
ZA (1) ZA200500015B (hr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US7365086B2 (en) * 2003-07-25 2008-04-29 Synthon Ip Inc. Pramipexole acid addition salts
ATE486588T1 (de) * 2004-08-13 2010-11-15 Boehringer Ingelheim Int Tablettenformulierung mit verlängerter freisetzung mit pramipexol oder einem pharmazeutisch zulässigen salz davon, herstellungsverfahren und verwendung dafür
CA2576386A1 (en) * 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
WO2006038339A1 (ja) * 2004-10-01 2006-04-13 Nippon Zoki Pharmaceutical Co., Ltd. 固形医薬製剤
WO2006046256A1 (en) * 2004-10-27 2006-05-04 Alembic Limited Extended release formulation of pramipexole dihydrochloride
US20090041844A1 (en) * 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
WO2007090882A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole
US20090098202A1 (en) * 2006-02-10 2009-04-16 Boehringer Ingelheim International Gmbh Extended Release Formulation
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
AU2007253899A1 (en) 2006-05-16 2007-11-29 Knopp Neurosciences, Inc. Compositions of R(+) and S(-) pramipexole and methods of using the same
US20080254118A1 (en) * 2007-04-11 2008-10-16 Hans-Werner Wernersbach Process for preparing pramipexole dihydrochloride tablets
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US10716798B2 (en) 2007-02-21 2020-07-21 The Regents Of The University Of Michigan Compositions and methods for tranquilizing heart muscle
RU2454409C2 (ru) 2007-03-14 2012-06-27 Нопп Ньюросайенсиз, Инк. Синтез хирально очищенных замещенных бензотиазолдиаминов
WO2008145252A1 (en) * 2007-05-25 2008-12-04 Boehringer Ingelheim International Gmbh Pharmaceutical formulation comprising pramipexole
WO2008150741A1 (en) * 2007-06-04 2008-12-11 Drugtech Corporation Controlled release dopamine agonist compositions
WO2009152041A2 (en) * 2008-06-09 2009-12-17 Supernus Pharmaceuticals, Inc. Controlled release formulations of pramipexole
CA2734491A1 (en) 2008-08-19 2010-02-25 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
WO2010115267A1 (en) * 2009-04-09 2010-10-14 Purdue Pharma Once-daily oral ir/cr pramipexole formulation
WO2011002891A1 (en) * 2009-07-02 2011-01-06 Supernus Pharmaceuticals, Inc. A method of treatment of a neurological disorder
WO2011037976A2 (en) * 2009-09-22 2011-03-31 Dr. Reddy's Laboratories Limited Pramipexole pharmaceutical formulations
EP2525786A2 (en) * 2010-01-18 2012-11-28 Synthon BV Pramipexole extended release tablets
TR201001862A1 (tr) * 2010-03-11 2011-10-21 Sanovel �La� San.Ve T�C.A.�. Kontrollü salım gerçekleştiren pramipeksol formülasyonları.
US20130209553A1 (en) 2010-04-15 2013-08-15 Cadila Healthcare Limited Extended release pharmaceutical compositions of pramipexole
AU2011256928A1 (en) 2010-05-24 2012-12-20 Lupin Limited Extended release formulation of pramipexole
CN102670550A (zh) * 2011-03-14 2012-09-19 北京天衡药物研究院 盐酸普拉克索渗透泵型控释片
WO2013034173A1 (en) 2011-09-06 2013-03-14 Synthon Bv Pramipexole extended release tablets
CN102406626B (zh) * 2011-12-02 2013-08-28 深圳海王药业有限公司 盐酸普拉克索缓释片剂及其制备方法
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
EP2732812A1 (de) 2012-11-15 2014-05-21 Aristo Pharma GmbH Pramipexol-Retardtablettenformulierung
CN103058953B (zh) * 2012-11-22 2015-03-25 刘炜 用于治疗神经疾病的四氢苯并噻唑衍生物
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
CN105764507B (zh) 2013-07-12 2019-07-19 诺普生物科学有限责任公司 治疗升高的嗜酸性粒细胞和/或嗜碱性粒细胞的水平
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
AU2014306683B2 (en) 2013-08-13 2017-10-12 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
ES2871556T3 (es) 2013-08-13 2021-10-29 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de la urticaria crónica
CN104606162B (zh) * 2015-01-07 2017-03-29 海南康虹医药科技开发有限公司 一种盐酸普拉克索缓释制剂及其制备方法
CN104784155B (zh) * 2015-05-15 2018-02-23 中国药科大学 一种盐酸普拉克索组合微丸胶囊及其制备方法
CN105030721B (zh) * 2015-08-30 2018-05-04 南京康川济医药科技有限公司 一种含有盐酸普拉克索的口服固体组合物
EP3522843B1 (en) * 2016-10-07 2022-09-21 Transwell Biotech Co., Ltd. Pramipexole transdermal delivery system and uses thereof
WO2018115338A1 (de) * 2016-12-21 2018-06-28 Hso Herbert Schmidt Gmbh & Co. Kg Beizlösung zum beizen von kunststoffen
BR112019022175A2 (pt) * 2017-04-24 2020-05-12 Chase Therapeutics Corporation Composições e método para tratamento de depressão
US11234961B2 (en) 2017-08-17 2022-02-01 Zi-Qiang Gu Pamoate salt of monoamine anti-Parkinson's agents, method of preparation and use thereof

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4731374A (en) * 1984-12-22 1988-03-15 Dr. Karl Thomae Gmbh Tetrahydro-benzthiazoles, the preparation thereof and their use as intermediate products or as pharmaceuticals
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
WO1999009066A1 (en) * 1997-08-14 1999-02-25 9068-3293 Quebec Inc. Preparation of pregelatinized high amylose starch and debranched starch useful as an excipient for controlled release of active agents
WO1999016442A2 (en) * 1997-09-30 1999-04-08 Pharmacia & Upjohn Company Sustained release tablet formulation to treat parkinson disease
EP0933079A1 (en) * 1998-02-03 1999-08-04 Cerestar Holding Bv Free-flowable, directly compressible starch as binder, disintegrant and filler for compression tablets and hard gelatine capsules
WO1999045924A1 (en) * 1998-03-11 1999-09-16 Smithkline Beecham Plc Composition
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
WO2000059477A1 (en) * 1999-03-31 2000-10-12 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
WO2001022820A1 (en) * 1999-09-30 2001-04-05 The General Hospital Corporation Use of pramipexole as a treatment for cocaine craving
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
US20020015735A1 (en) * 1999-12-22 2002-02-07 Hedden David B. Sustained-release formulation of a cyclooxygenase-2 inhibitor

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2887440A (en) * 1957-08-12 1959-05-19 Dow Chemical Co Enteric coating
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
NL265428A (hr) * 1960-06-06
US3458622A (en) * 1967-04-07 1969-07-29 Squibb & Sons Inc Controlled release tablet
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
JPS58403B2 (ja) * 1975-07-24 1983-01-06 武田薬品工業株式会社 Ｌ− アスコルビンサンセイザイノ セイゾウホウ
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
SE8003805L (sv) 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap
SE8103843L (sv) * 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4738851A (en) * 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US4666612A (en) * 1986-03-17 1987-05-19 Kerr-Mcgee Chemical Corporation Method for recovering a wood preservative from waste sludges
US4772473A (en) * 1986-06-16 1988-09-20 Norwich Eaton Pharmaceuticals, Inc. Nitrofurantoin dosage form
US4709712A (en) * 1986-10-22 1987-12-01 Dermatalogical Products Of Texas Polycarboxylic acid polymer gels as protective agents
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4789549A (en) * 1987-03-09 1988-12-06 Warner-Lambert Company Sustained release dosage forms
US4859470A (en) * 1988-06-02 1989-08-22 Alza Corporation Dosage form for delivering diltiazem
GB8828020D0 (en) * 1988-12-01 1989-01-05 Unilever Plc Topical composition
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5273975A (en) * 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
FR2653337B1 (fr) 1989-10-23 1992-02-07 Dow Corning Sa Element a liberation prolongee et procede pour le fabriquer.
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
EP0447168A3 (en) 1990-03-16 1993-01-07 Yamanouchi Pharmaceutical Co. Ltd. Long acting granular pharmaceutical composition
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5656296A (en) * 1992-04-29 1997-08-12 Warner-Lambert Company Dual control sustained release drug delivery systems and methods for preparing same
US5661171A (en) * 1992-07-02 1997-08-26 Oramed, Inc. Controlled release pilocarpine delivery system
CZ291495B6 (cs) 1992-09-18 2003-03-12 Yamanouchi Pharmaceutical Co., Ltd. Hydrogelotvorný farmaceutický přípravek s prodlouženým uvolňováním
DE4241013A1 (de) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5458887A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5484608A (en) 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
DE4432757A1 (de) 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
US5650420A (en) 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
EP0869772B1 (en) 1995-12-27 2001-10-04 Janssen Pharmaceutica N.V. Bioadhesive solid dosage form
US5846971A (en) * 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
JPH1017497A (ja) 1996-07-02 1998-01-20 Takeda Chem Ind Ltd 徐放性製剤およびその製造方法
GB9619074D0 (en) 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
PT998271E (pt) * 1997-06-06 2005-10-31 Depomed Inc Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
CA2270975C (en) 1997-07-02 2003-04-01 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
US6248358B1 (en) * 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
DE69819748T2 (de) * 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6624200B2 (en) * 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
SK285068B6 (sk) 1997-09-29 2006-05-04 Nektar Therapeutics Práškový prostriedok, mikrosféry, spôsob tvorby časticového prostriedku obsahujúceho perforované mikroštruktúry prostredníctvom sušenia striekaním a spôsob tvorby prášku obsahujúceho perforované mikroštruktúry prostredníctvom sušenia striekaním
US20020013304A1 (en) 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US20020054911A1 (en) * 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
PL344574A1 (en) 1998-05-15 2001-11-05 Upjohn Co Cabergoline and pramipexole: new uses and combinations
US6312728B1 (en) 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
TW407058B (en) * 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
US20010055613A1 (en) 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
US6270805B1 (en) 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
DE19927688A1 (de) * 1999-06-17 2000-12-21 Gruenenthal Gmbh Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
EP1261340B1 (en) * 1999-07-13 2009-05-13 Alpha Research Group, LLC Compositions and methods for the treatment of parkinson's disease
GB9923045D0 (en) 1999-09-29 1999-12-01 Novartis Ag New oral formulations
AU780505B2 (en) 1999-10-19 2005-03-24 Nps Pharmaceuticals, Inc. Sustained-release formulations for treating CNS-mediated disorders
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2332691C (en) * 2000-01-27 2007-11-27 The York Group, Inc. Death care merchandising system
NZ520554A (en) 2000-02-08 2005-08-26 Euro Celtique S Tamper-resistant oral opioid agonist formulations
PE20011074A1 (es) * 2000-02-23 2001-10-04 Upjohn Co Uso de pramipexol en el tratamiento de trastornos de adiccion
CN1396829A (zh) * 2000-02-24 2003-02-12 法玛西雅厄普约翰美国公司 新的药物联合形式
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
HUP0303355A3 (en) * 2000-08-08 2005-06-28 Teva Pharma Stable pergolide mesylate and process for making same
ES2187249B1 (es) 2000-09-18 2004-09-16 Synthon Bv Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
SE0004671D0 (sv) * 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
WO2003011255A1 (en) 2001-07-04 2003-02-13 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
FR2827872A1 (fr) 2001-07-30 2003-01-31 Roussy Inst Gustave Vesicules membranaires de fluide biologique preleve in vivo, leur preparation et utilisation dans la stimulation d'une reponse immunitaire
US20030032661A1 (en) * 2001-08-02 2003-02-13 Boehringer Ingelheim Pharma Kg Pramipexole as an anticonvulsant
GB0125088D0 (en) 2001-10-18 2001-12-12 Smithkline Beecham Cork Ltd New use
BR0215262A (pt) 2001-12-20 2004-12-28 Pharmacia Corp Formas de dosagem com liberação sustentada de ordem zero e processo para a fabricação das mesmas
AU2003202879A1 (en) 2002-01-04 2003-07-24 Ivax Research, Inc. Drug delivery system for sustained delivery of glipizide
BR0308137A (pt) 2002-03-04 2005-01-04 Sod Conseils Rech Applic Formulações de droga de liberação constante contendo um peptìdeo veìculo
KR20040098050A (ko) 2002-04-05 2004-11-18 유로-셀띠끄 소시에떼 아노님 옥시코돈 및 날록손을 포함하는 약제학적 제제
CN1655766B (zh) 2002-04-15 2012-05-30 利洁时有限责任公司 愈创甘油醚组合药物的持续释放
US20030215498A1 (en) * 2002-05-17 2003-11-20 Harland Ronald S. Rapidly disintegrating comressed tablets comprising biologically active compounds
EP1519720A4 (en) 2002-06-10 2010-02-10 Wyeth Corp NOVEL O-DESMETHYLVENLAFAXINE FORMALITY SALT
MXPA05000018A (es) 2002-06-27 2005-04-08 Cilag Ag Formulaciones de pellas esfericas.
AU2003281181A1 (en) * 2002-07-11 2004-02-02 Takeda Pharmaceutical Company Limited Process for producing coated preparation
JP2005538105A (ja) 2002-07-25 2005-12-15 ファルマシア・コーポレーション 水不溶性ポリマーおよび水溶性の小孔形成物質からなる２層により被覆された固体剤形の製造方法
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
AR040680A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Composicion de tabletas de liberacion sostenida
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
CA2415154C (en) 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
WO2004058228A1 (en) 2002-12-24 2004-07-15 Lupin Limited Enteric coated fluoxetine composition
US20050020589A1 (en) * 2003-06-18 2005-01-27 Pfizer Inc. Sustained-release tablet composition comprising a dopamine receptor agonist
CA2576386A1 (en) * 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
ATE486588T1 (de) * 2004-08-13 2010-11-15 Boehringer Ingelheim Int Tablettenformulierung mit verlängerter freisetzung mit pramipexol oder einem pharmazeutisch zulässigen salz davon, herstellungsverfahren und verwendung dafür
US20090098202A1 (en) * 2006-02-10 2009-04-16 Boehringer Ingelheim International Gmbh Extended Release Formulation
US20090041844A1 (en) * 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
EP1886665A1 (en) * 2006-08-01 2008-02-13 Boehringer Ingelheim Pharma GmbH & Co. KG Gastro retentive delivery system
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
CN101505736A (zh) * 2006-08-25 2009-08-12 贝林格尔.英格海姆国际有限公司 控制释放系统及其制造方法

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4731374A (en) * 1984-12-22 1988-03-15 Dr. Karl Thomae Gmbh Tetrahydro-benzthiazoles, the preparation thereof and their use as intermediate products or as pharmaceuticals
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
WO1999009066A1 (en) * 1997-08-14 1999-02-25 9068-3293 Quebec Inc. Preparation of pregelatinized high amylose starch and debranched starch useful as an excipient for controlled release of active agents
WO1999016442A2 (en) * 1997-09-30 1999-04-08 Pharmacia & Upjohn Company Sustained release tablet formulation to treat parkinson disease
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
EP0933079A1 (en) * 1998-02-03 1999-08-04 Cerestar Holding Bv Free-flowable, directly compressible starch as binder, disintegrant and filler for compression tablets and hard gelatine capsules
WO1999045924A1 (en) * 1998-03-11 1999-09-16 Smithkline Beecham Plc Composition
WO2000059477A1 (en) * 1999-03-31 2000-10-12 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
WO2001022820A1 (en) * 1999-09-30 2001-04-05 The General Hospital Corporation Use of pramipexole as a treatment for cocaine craving
US20020015735A1 (en) * 1999-12-22 2002-02-07 Hedden David B. Sustained-release formulation of a cyclooxygenase-2 inhibitor
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia

Also Published As

Publication number Publication date
EP2289514B9 (en) 2013-08-21
MA27372A1 (fr) 2005-06-01
JP2005538995A (ja) 2005-12-22
RS52764B (en) 2013-10-31
CY1114263T1 (el) 2016-08-31
SI1536792T1 (sl) 2013-11-29
PT1536792E (pt) 2013-12-02
KR20070062614A (ko) 2007-06-15
AR040682A1 (es) 2005-04-13
NO20050481L (no) 2005-01-27
PL375444A1 (en) 2005-11-28
DE20321906U1 (de) 2012-11-07
DK2289514T5 (da) 2013-09-30
OA12889A (en) 2006-10-13
BR0312948A (pt) 2005-06-14
MXPA05000980A (es) 2005-09-12
EP2289514B1 (en) 2013-06-19
AU2003256921B2 (en) 2009-03-05
CA2493629C (en) 2013-10-08
US8679533B2 (en) 2014-03-25
HK1078007A1 (en) 2006-03-03
PE20040134A1 (es) 2004-03-06
PA8578501A1 (es) 2005-02-04
CA2493629A1 (en) 2004-02-05
ES2421787T9 (es) 2013-11-06
ECSP055569A (es) 2005-04-18
ZA200500015B (en) 2006-07-26
SI2289514T1 (sl) 2013-08-30
NZ562681A (en) 2009-11-27
DK2289514T3 (da) 2013-08-05
HRP20041234A2 (en) 2005-04-30
PT2289514E (pt) 2013-07-23
CY1114566T1 (el) 2016-10-05
CU23468B7 (es) 2009-12-17
KR20050025654A (ko) 2005-03-14
RS115104A (en) 2006-12-15
GEP20074047B (en) 2007-02-26
EP2289514A1 (en) 2011-03-02
US20140141079A1 (en) 2014-05-22
AP2223A (en) 2011-03-24
MEP52208A (en) 2011-02-10
CN1671381B (zh) 2010-10-27
EP1536792A1 (en) 2005-06-08
ES2421787T3 (es) 2013-09-05
CN1671381A (zh) 2005-09-21
JP4607584B2 (ja) 2011-01-05
KR101066374B1 (ko) 2011-09-20
EA200500080A1 (ru) 2005-06-30
IS7613A (is) 2004-12-23
UY27913A1 (es) 2004-02-27
US20050175691A1 (en) 2005-08-11
DK1536792T3 (da) 2013-11-11
SG177011A1 (en) 2012-01-30
EP1536792B1 (en) 2013-09-18
ES2436745T3 (es) 2014-01-07
MY142204A (en) 2010-10-29
ME00347B (me) 2011-05-10
WO2004010999A1 (en) 2004-02-05
AP2005003206A0 (en) 2005-03-31
TW200418465A (en) 2004-10-01
EA017595B1 (ru) 2013-01-30
TWI351955B (en) 2011-11-11
AU2003256921A1 (en) 2004-02-16
IL166076A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
HRP20041234B1 (hr) Oblik pramipeksola za doziranje jednom dnevno
NO20052019L (no) Blanding for a inhibere sekresjon av magesyre
NO20051854L (no) Vedvarende frigivelse opioidformuleringer og fremgangsmater for anvendelse.
EA200900264A1 (ru) Композиции флибансерина и способ их приготовления
ES2170069T3 (es) 1-alfa-hidroxiprevitamina d para administracion oral.
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
WO2003013433A3 (en) Sequestered antagonist formulations
KR20220140647A (ko) 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
FI3067043T3 (fi) Angiotensiinireseptoriantagonistin/-salpaajan (arb) ja neutraalin endopeptidaasin (nep) estäjän superrakenteisiin perustuvia farmaseuttisia koostumuksia
JP2010530422A (ja) うつ病のための組合せ治療
AR040709A1 (es) Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion
HUP0204163A2 (hu) Opioid agonistát és antagonistát tartalmazó szabályozott leadású készítmény és eljárás az előállítására
KR20110055604A (ko) Ｃｎｓ 장애의 치료 및 예방을 위한 위 체류성 약학적 조성물
RU2005115855A (ru) Композиция трамадола продлонгированного высвобождением с 24-часовым действием
IL149496A (en) Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract
KR102624627B1 (ko) 지연 방출 데페리프론 정제 및 그의 사용 방법
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
AR062659A1 (es) Composicion de liberacion sostenida de levodopa y metodo para su uso
BRPI0412430A (pt) polipeptìdeo agonista do receptor de zot e zonulina
DE60035579D1 (de) Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme
UY28457A1 (es) Nueva composición
AR046454A1 (es) Uso de un compuesto de acido benzazepin-n-acetico, composicion farmaceutica, y procedimiento para la produccion de dicha composicion farmaceutica
DE69103724D1 (de) Pharmazeutische zusammensetzungen mit verzögerter freisetzung zur oralen verabreichung sowie deren herstellungsverfahren.
IS6504A (is) Ný galensk lyfjablanda með hægri losun á molsidómíni
CR7660A (es) Forma de dosificacion de pramipexol en una dosis unica diaria

Legal Events

Date Code Title Description
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
A1OB Publication of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20190711

Year of fee payment: 17

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200722

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20210713

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20220713

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20230725